LEO Pharma to Highlight Data at 28th Congress of the European Academy of Dermatology (EADV)

Data will communicate new and updated findings, including in the treatment of psoriasis, atopic dermatitis and chronic hand eczema

BALLERUP, Denmark--()--LEO Pharma A/S, a global leader in medical dermatology, today announced that data from company-sponsored, health economic outcome and investigator-initiated studies will be presented at the 28th annual Congress of the European Academy of Dermatology (EADV), Oct. 9-13, in Madrid, Spain. The scope of research continues to evaluate the company’s approved and investigational therapies toward the company’s mission to help people achieve healthy skin.

Data that LEO Pharma will present at EADV show how we continue to pioneer medical dermatology with the goal to constantly improve what is possible for patients,” said Kim Kjoeller, Executive Vice President, Global Research & Development, LEO Pharma. “We believe significant unmet needs remain for people affected by psoriasis and eczema – both common and debilitating skin diseases with profound effects on the quality of life of people around the world.”

Abstracts are accessible via computers in the EADV Congress e-Poster Hall during congress hours.

Contacts

Henrik Kyndlev
Global External Communications
+45 3140 6180
hdtdk@leo-pharma.com

Kimberly Whitefield
Global Product Communications, Eczema
+1 862 345 0643
kqwus@leo-pharma.com

Release Summary

LEO Pharma to highlight data at 28th Congress of the European Academy of Dermatology (EADV)

Contacts

Henrik Kyndlev
Global External Communications
+45 3140 6180
hdtdk@leo-pharma.com

Kimberly Whitefield
Global Product Communications, Eczema
+1 862 345 0643
kqwus@leo-pharma.com